$PMI

PMI revenues top $11bn as IQOS grows share in Global Travel Retail

Philip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.

Original reporting
Published Jul 27, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PMI revenues top $11bn as IQOS grows share in Global Travel Retail — source image
Decision brief

The 30-second read

$PMIBullishMed
01

Why it matters

Q2 performance shows strong top-line and operating income growth, with smoke-free mix rising to about 42% of group revenues. The quantified IQOS offtake share gain in Global Travel Retail airports provides a channel-level indicator of competitive traction, while Middle East disruption is framed as manageable but volatile.

02

Market read

Traders can update expectations for PMI’s smoke-free growth and competitive share in travel retail, while monitoring cost inflation risk from the Middle East.

03

What to watch

Shipment volume growth is positive, but the article emphasizes that full-year forecast does not assume prolonged impact, so any escalation could quickly change the cost and consumer-behavior outlook.

Relevance 8/10Novelty 6/10Timing: post-Q2 results, positioning ahead of full-year target monitoring

Background

PMI is in the middle of its smoke-free transition strategy, with IQOS heated tobacco and other smoke-free categories (VEEV, modern oral, ZYN) expanding across markets.

Company-level read

Ticker impact

$PMIBullishMedium confidence
Context

PMI reported Q2 2026 net revenues of $11.2bn, up 10.4% YoY, with smoke-free shipments up 7.5% and IQOS offtake share rising in Global Travel Retail airports.

Expected impact

Bias modestly positive for PMI, with upside sensitivity to any follow-through in smoke-free share gains and transport cost inflation staying contained.

Evidence & confidence

The article provides multiple fresh, quantified operating datapoints (revenues, operating income, shipment mix, and IQOS offtake share) and reiterates full-year outlook assumptions not assuming prolonged Middle East impact.

Market effects

Reinforces the tobacco sector’s ongoing shift toward smoke-free products, with measurable retail channel share gains for heated tobacco.

Highlights Global Travel Retail airports as a key growth channel, with specific city-level offtake share increases.

Middle East conflict is framed as cost-inflation pressure rather than demand destruction, which may influence broader risk sentiment for consumer staples with regional logistics exposure.

Counterpoint

The company flags volatility and cost pressures from the Middle East, and it does not disclose Global Travel Retail revenue, limiting how much the IQOS share gain can translate into earnings upside.

Key entities

  • Philip Morris International

    Reported Q2 2026 net revenues of $11.2bn, operating income of $4.5bn, and quantified smoke-free and IQOS channel metrics.

  • IQOS

    Heated tobacco brand; reported 21.5% offtake share in Global Travel Retail airports where available between March and May 2026.

  • Global Travel Retail

    Airport retail channel identified as contributing notably to international smoke-free shipment volume growth.

Related articles

$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

$PMIMedAI 8/10

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical (NYSE American: PMI), parent of SynCardia, said it completed an acute in vivo implant study series of its next-generation Emperor Total Artificial Heart at the University of Arizona and Banner University Medical Center. Three procedures showed stable full circulatory support with no device-related intraoperative failures, using an independent dual-motor ventricular design. The Emperor TAH remains under development and is not FDA approved.